Monday, November 14, 2016
- 9:00AM-11:00AM
-
Abstract Number: 1645
Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of ASP5094, an Anti-Alpha-9-Integrin Monoclonal Antibody, Following Single Intravenous Doses in Healthy Subjects
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1634
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1629
Pharmacokinetics of ABT-494 with the Once-Daily Extended-Release Tablet Formulation Being Utilized in the Ongoing Rheumatoid Arthritis Phase 3 Trials
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1620
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MEDI4920, a Novel, Engineered CD40 Ligand Antagonist, in Healthy Volunteers
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1695
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1783
Phenome-Wide Association Study Identifies a New Association of Atrial Fibrillation in Males with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1951
Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Vasculitis - Poster II: ANCA-Associated Vasculitis- 9:00AM-11:00AM
-
Abstract Number: 1858
Phenotypical and Functional Characteristics of in Vitro Expanded Adipose-Derived Mesenchymal Stem Cells from Patients with Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1855
Phosphodiesterase-5 Inhibitors Attenuate Fibrotic Phenotype and Restore Anti-Fibrotic Resopnses of Cutaneous Fibroblasts in Patients with Scleroderma
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1758
Physical Activity and Sedentary Behaviour in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life- 9:00AM-11:00AM
-
Abstract Number: 1875
Physical Activity in Patients with Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1539
Physician-Reported and Patient-Reported Anxiety and Depression in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1264
Pilot Evaluation Points to Male Specific Educational Programming for Males with SLE
Healthcare Disparities in Rheumatology - ARHP Poster- 9:00AM-11:00AM
-
Abstract Number: 1671
Pirfenidone Might Inhibit New Bone Formation in Spondyloarthritis: Proof of Concept Study Using Cell Culture Models